Moneycontrol
HomeNewsBusinessMarketsWe are entering a period of multi-year growth in profits ideal for a long-lasting bull market: Dipan Mehta
Trending Topics

We are entering a period of multi-year growth in profits ideal for a long-lasting bull market: Dipan Mehta

Risk return favours buying small/midcap stocks which have good management, corporate governance standards, and clean balance sheets, said Mehta.

June 09, 2021 / 08:10 IST
Story continues below Advertisement

Dipan Mehta, Director at Elixir Equities Pvt Ltd, said that we are on the cusp of entering a period of multi-year growth in profits which is the ideal scenario for a sustainable and long-lasting bull market.

Here are the edited excerpts from his interview with Moneycontrol's Kshitij Anand:

Story continues below Advertisement

Q) The Nifty50 hit a fresh record high above 15700 for the first time. What is your outlook on markets for 2021?

A) Despite all the gloom and doom caused by the second Covid wave, markets are in the pink of health. The bounce in the economy after the first lockdown was lifted is fresh in investors’ memory and the Street is pricing a similar recovery once the intermittent lockdowns are lifted and life limps back to normalcy.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show